Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPCLTW)

• Drug Name: dodecylphosphate Drug Info
• Synonyms: FAP12; dodecanol phosphate; FAP-12; lauryl phosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1550836
  TTD Drug ID: DMPCLTW

Molecule-Related Drug Atlas

Drug(s) Targeting Lysophosphatidic acid receptor 2 (LPAR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LPA	DMI5XR1	Discovery agent	N.A.	Investigative	[3]
Ki16425	DMJTDK9	Discovery agent	N.A.	Investigative	[4]
2-oleoyl-LPA	DMN9OS1	Discovery agent	N.A.	Investigative	[5]
dodecyl-thiophosphate	DMAJVPI	Discovery agent	N.A.	Investigative	[6]
oleoyl-thiophosphate	DM1TAM9	Discovery agent	N.A.	Investigative	[6]
NAEPA	DM38XWZ	Discovery agent	N.A.	Investigative	[7]
BrP-LPA	DMPGEO1	Discovery agent	N.A.	Investigative	[8]
PMID18178086C15	DMA2OWK	Discovery agent	N.A.	Investigative	[9]
decyl dihydrogen phosphate	DMNKDT5	Discovery agent	N.A.	Investigative	[2]
GRI977143	DM3A0TE	Discovery agent	N.A.	Investigative	[10]

Drug(s) Targeting Lysophosphatidate-3 receptor (LPAR3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR-100842	DMDMQW0	Fibrosis	GA14-GC01	Phase 2	[11]
LPA	DMI5XR1	Discovery agent	N.A.	Investigative	[12]
Ki16425	DMJTDK9	Discovery agent	N.A.	Investigative	[4]
dioctanoylglycerol pyrophosphate	DM0QY1V	Discovery agent	N.A.	Investigative	[13]
2-oleoyl-LPA	DMN9OS1	Discovery agent	N.A.	Investigative	[5]
dodecyl-thiophosphate	DMAJVPI	Discovery agent	N.A.	Investigative	[6]
oleoyl-thiophosphate	DM1TAM9	Discovery agent	N.A.	Investigative	[6]
VPC12249	DM6F0VR	Discovery agent	N.A.	Investigative	[14]
NAEPA	DM38XWZ	Discovery agent	N.A.	Investigative	[7]
VPC32183	DMLK3I9	Discovery agent	N.A.	Investigative	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysophosphatidate-3 receptor (LPAR3)	TTE2YJR	LPAR3_HUMAN	Antagonist	[2]
Lysophosphatidic acid receptor 2 (LPAR2)	TTB7Y8I	LPAR2_HUMAN	Agonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4031).
• [2] Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
• [3] Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3473-6.
• [4] Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
• [5] Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
• [6] Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
• [7] LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
• [8] Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
• [9] Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
• [10] Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73.
• [11] Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
• [12] Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999 Sep 24;274(39):27776-85.
• [13] Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
• [14] Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80.
• [15] Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.